期刊
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
卷 28, 期 6, 页码 1924-1932出版社
AMER SOC NEPHROLOGY
DOI: 10.1681/ASN.2016080918
关键词
-
资金
- Agence Nationale pour le Recherche [ANR-16-CE14-0019-01]
- Federation Nationale pour l'Aide aux Insuffisants Renaux
- Fondation du Rein
- l'Agence de la Biomedecine
- Agence Nationale de la Recherche (ANR) [ANR-16-CE14-0019] Funding Source: Agence Nationale de la Recherche (ANR)
CKD occurs in most patients with acute intermittent porphyria (AIP). During AIP, delta-aminolevulinic acid (ALA) accumulates and promotes tubular cell death and tubulointerstitial damage. The human peptide transporter 2 (PEPT2) expressed by proximal tubular cells mediates the reabsorption of ALA, and variants of PEPT2 have different affinities for ALA. We tested the hypothesis that PEPT2 genotypes affect the severity and prognosis of porphyria-associated kidney disease. We analyzed data from 122 individuals with AIP who were followed from 2003 to 2013 and genotyped for PEPT2. At last follow-up, carriers of the PEPT2*1*1 genotype (higher affinity variant) exhibited worse renal function than carriers of the lower affinity variants PEPT2*1/*2 and PEPT2*2/*2 (mean+/-SD eGFR: 54.4+/-19.1, 66.6+/-23.8, and 78.1+/-19.9 ml/min per 1.73 m(2), respectively). Change in eGFR (mean+/-SD) over the 10-year period was -11.0+/-3.3, -2.4+/-1.9, and 3.4+/-2.6 ml/min per 1.73 m(2) for PEPT2*1/*1, PEPT2*1*2, and PEPT*2*2*2 carriers, respectively. At the end of follow-up, 68% of PEPT2*1*1 carriers had an eGFR<60 ml/min per 1.73 m2, compared with 37% of PEPT2*1*2 carriers and 15% of PEPT2*2*2 carriers. Multiple regression models including all confounders indicated that the PEPT2*1*1 genotype independently associated with an eGFR<60 ml/min per 1.73 m2 (odds ratio, 6.85; 95% confidence interval, 1.34 to 46.20) and an annual decrease in eGFR of >1 ml/min per 1.73 m2 (odds ratio, 3.64; 95% confidence interval, 1.37 to 9.91). Thus, a gene variant is predictive of the severity of a chronic complication of AIP. The therapeutic value of PEPT2 inhibitors in preventing porphyria-associated kidney disease warrants investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据